United States

Analyst Research Report Snapshot


Astellas Pharma Inc. (4503) - Financial and Strategic SWOT Analysis Review






11 Jul 2014





Companies referenced:


Available for Immediate Download

Astellas Pharma Inc. (4503) - Financial and Strategic SWOT Analysis Review Summary Astellas Pharma Inc. (Astellas) is one of the leading global pharmaceutical companies. It undertakes the research, development, manufacture and commercialization of a wide range of pharmaceuticals. The company’s product portfolio comprises both marketed and pipeline products to treat a wide range of diseases related conditions in urology, transplantation, immune deficiency, infectious diseases, cancer, neuroscience, and metabolic diseases, among others. Astellas Pharma Inc. Key Recent Developments: Jan 06, 2014: Astellas to form partnership with Clearpath to build vaccine portfoli Oct 01, 2013: Establishment of New Organization to enhance the ability to generate innovative drugs Sep 27, 2013: Production Subsidiary Astellas Pharma Tech Concludes Basic Agreement with Nichi-Iko on Succession of Fuji Plant Business Aug 22, 2013: International partnership receives funding to develop a drug product to fight schistosomiasis (bilharzia) in children Aug 19, 2013: iNTRODB receives the Minister of Health, Labour and Welfare Award of the 11th annual Merit Awards for Industry-Academia-Government Collaboration This comprehensive SWOT profile of Astellas Pharma Inc. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description - A detailed description of the company's operations and business divisions. - Corporate strategy - Analyst's summarization of the company's business strategy. - SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities - A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and r...

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.